{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:44:32Z","timestamp":1791308672828,"version":"4.3.1"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.antiviral.2014.05.017","type":"journal-article","created":{"date-parts":[[2014,6,5]],"date-time":"2014-06-05T12:41:45Z","timestamp":1401972105000},"page":"94-103","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Cloning of the first human anti-JCPyV\/VP1 neutralizing monoclonal antibody: Epitope definition and implications in risk stratification of patients under natalizumab therapy"],"prefix":"10.1016","volume":"108","author":[{"given":"Roberta Antonia","family":"Diotti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicasio","family":"Mancini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Clementi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Sautto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guisella Janett","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0185-3147","authenticated-orcid":false,"given":"Elena","family":"Criscuolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8347-5903","authenticated-orcid":false,"given":"Francesca","family":"Cappelletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Man","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Forest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Remy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3374-7621","authenticated-orcid":false,"given":"Simone","family":"Giannecchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Clementi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Burioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2014.05.017_b0005","first-page":"1374","article-title":"Progressive multifocal leukoencephalopathy","volume":"18","author":"Aksamit","year":"2012","journal-title":"Continuum (Minneap Minn)"},{"key":"10.1016\/j.antiviral.2014.05.017_b0010","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0304-3940(96)12389-2","article-title":"Antibody against synthetic multiple antigen peptides (MAP) of JC virus capsid protein (VP1) without cross reaction to BK virus: a diagnostic tool for progressive multifocal leukoencephalopathy","volume":"205","author":"Aoki","year":"1996","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.antiviral.2014.05.017_b0015","first-page":"93","article-title":"Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin\u2019s disease","volume":"81","author":"Astrom","year":"1958","journal-title":"Brain"},{"key":"10.1016\/j.antiviral.2014.05.017_b0020","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/13550280152537157","article-title":"A combination of low-dose chlorpromazine and neutralizing antibodies inhibits the spread of JC virus (JCV) in a tissue culture model: implications for prophylactic and therapeutic treatment of progressive multifocal leukoencephalopathy","volume":"7","author":"Atwood","year":"2001","journal-title":"J. Neurovirol."},{"key":"10.1016\/j.antiviral.2014.05.017_b0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13365-012-0080-7","article-title":"Human polyomavirus JC reactivation and pathogenetic mechanisms of progressive multifocal leukoencephalopathy and cancer in the era of monoclonal antibody therapies","volume":"18","author":"Bellizzi","year":"2012","journal-title":"J. Neurovirol."},{"key":"10.1016\/j.antiviral.2014.05.017_b0030","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2014.05.017_b0035","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1080\/13550280390218887","article-title":"Analysis of the excreted JC virus strains and their potential oral transmission","volume":"9","author":"Bofill-Mas","year":"2003","journal-title":"J. Neurovirol."},{"key":"10.1016\/j.antiviral.2014.05.017_b0040","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1006\/viro.2000.0451","article-title":"Purified JC virus T and T\u2032 proteins differentially interact with the retinoblastoma family of tumor suppressor proteins","volume":"274","author":"Bollag","year":"2000","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2014.05.017_b0045","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/ana.22606","article-title":"Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1","volume":"70","author":"Bozic","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.antiviral.2014.05.017_b0050","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0733-8619(18)31105-8","article-title":"Progressive multifocal leukoencephalopathy","volume":"2","author":"Brooks","year":"1984","journal-title":"Neurol. Clin."},{"key":"10.1016\/j.antiviral.2014.05.017_b0055","doi-asserted-by":"crossref","first-page":"9986","DOI":"10.1128\/JVI.75.20.9986-9990.2001","article-title":"Mapping B-cell epitopes of hepatitis C virus E2 glycoprotein using human monoclonal antibodies from phage display libraries","volume":"75","author":"Bugli","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.05.017_b0060","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0022-1759(98)00102-1","article-title":"A vector for the expression of recombinant monoclonal Fab fragments in bacteria","volume":"217","author":"Burioni","year":"1998","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.antiviral.2014.05.017_b0065","doi-asserted-by":"crossref","first-page":"11775","DOI":"10.1128\/JVI.76.22.11775-11779.2002","article-title":"Diverging effects of human recombinant anti-hepatitis C virus (HCV) antibody fragments derived from a single patient on the infectivity of a vesicular stomatitis virus\/HCV pseudotype","volume":"76","author":"Burioni","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.05.017_b0070","doi-asserted-by":"crossref","first-page":"e3423","DOI":"10.1371\/journal.pone.0003423","article-title":"Anti-HIV-1 response elicited in rabbits by anti-idiotype monoclonal antibodies mimicking the CD4-binding site","volume":"3","author":"Burioni","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2014.05.017_b0075","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jhep.2008.05.008","article-title":"Perspectives for the utilization of neutralizing human monoclonal antibodies as anti-HCV drugs","volume":"49","author":"Burioni","year":"2008","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2014.05.017_b0080","first-page":"319","article-title":"Molecular cloning of the first human monoclonal antibodies neutralizing with high potency swine-origin influenza A pandemic virus (S-OIV)","volume":"32","author":"Burioni","year":"2009","journal-title":"New Microbiol."},{"key":"10.1016\/j.antiviral.2014.05.017_b0085","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.4049\/jimmunol.0901076","article-title":"Antigen-driven evolution of B lymphocytes in coronary atherosclerotic plaques","volume":"183","author":"Burioni","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.antiviral.2014.05.017_b0090","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.virol.2009.12.014","article-title":"Monoclonal antibodies isolated from human B cells neutralize a broad range of H1 subtype influenza A viruses including swine-origin influenza virus (S-OIV)","volume":"399","author":"Burioni","year":"2010","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2014.05.017_b0095","doi-asserted-by":"crossref","first-page":"10047","DOI":"10.1128\/JVI.00984-13","article-title":"Residue-level prediction of HIV-1 antibody epitopes based on neutralization of diverse viral strains","volume":"87","author":"Chuang","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.05.017_b0100","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S1473-3099(09)70226-9","article-title":"Progressive multifocal leukoencephalopathy in HIV-1 infection","volume":"9","author":"Cinque","year":"2009","journal-title":"Lancet Infect. Dis"},{"key":"10.1016\/j.antiviral.2014.05.017_b0105","doi-asserted-by":"crossref","first-page":"e28001","DOI":"10.1371\/journal.pone.0028001","article-title":"A human monoclonal antibody with neutralizing activity against highly divergent influenza subtypes","volume":"6","author":"Clementi","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2014.05.017_b0110","doi-asserted-by":"crossref","first-page":"8273","DOI":"10.3390\/ijms13078273","article-title":"Phage display-based strategies for cloning and optimization of monoclonal antibodies directed against human pathogens","volume":"13","author":"Clementi","year":"2012","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.antiviral.2014.05.017_b0115","doi-asserted-by":"crossref","first-page":"e34415","DOI":"10.1371\/journal.pone.0034415","article-title":"A non-VH1-69 heterosubtypic neutralizing human monoclonal antibody protects mice against H1N1 and H5N1 viruses","volume":"7","author":"De Marco","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2014.05.017_b0120","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/13550280802425467","article-title":"JC virus VP1 loop-specific polymorphisms are associated with favorable prognosis for progressive multifocal leukoencephalopathy","volume":"15","author":"Delbue","year":"2009","journal-title":"J. Neurovirol."},{"key":"10.1016\/j.antiviral.2014.05.017_b0125","first-page":"475","article-title":"Neutralization activity and kinetics of two broad-range human monoclonal IgG1 derived from recombinant Fab fragments and directed against Hepatitis C virus E2 glycoprotein","volume":"35","author":"Diotti","year":"2012","journal-title":"New Microbiol."},{"key":"10.1016\/j.antiviral.2014.05.017_b0130","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s00018-005-5454-z","article-title":"The human polyomaviruses","volume":"63","author":"Eash","year":"2006","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.antiviral.2014.05.017_b0135","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1086\/597126","article-title":"Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors","volume":"199","author":"Egli","year":"2009","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2014.05.017_b0140","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1128\/CMR.05031-11","article-title":"Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain","volume":"25","author":"Ferenczy","year":"2012","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.antiviral.2014.05.017_b0145","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1128\/JVI.32.2.476-482.1979","article-title":"Infectivity of the DNA from four isolates of JC virus","volume":"32","author":"Frisque","year":"1979","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.05.017_b0150","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0166-0934(96)02117-9","article-title":"Efficient production of JC virus in SVG cells and the use of purified viral antigens for analysis of specific humoral and cellular immune response","volume":"63","author":"Frye","year":"1997","journal-title":"J. Virol. Methods"},{"key":"10.1016\/j.antiviral.2014.05.017_b0155","doi-asserted-by":"crossref","first-page":"49172","DOI":"10.1074\/jbc.M409326200","article-title":"Modeling a sialic acid binding pocket in the external loops of JC virus VP1","volume":"279","author":"Gee","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2014.05.017_b0160","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ana.22128","article-title":"Anti-JC virus antibodies: implications for PML risk stratification","volume":"68","author":"Gorelik","year":"2010","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.antiviral.2014.05.017_b0165","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/infdis\/jir198","article-title":"Progressive multifocal leukoencephalopathy (PML) development is associated with mutations in JC virus capsid protein VP1 that change its receptor specificity","volume":"204","author":"Gorelik","year":"2011","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2014.05.017_b0170","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1128\/AAC.00046-11","article-title":"CMX001 (1-O-hexadecyloxypropyl-cidofovir) inhibits polyomavirus JC replication in human brain progenitor-derived astrocytes","volume":"55","author":"Gosert","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2014.05.017_b0175","doi-asserted-by":"crossref","first-page":"5335","DOI":"10.1128\/JVI.72.7.5335-5342.1998","article-title":"Archetype JC virus efficiently replicates in COS-7 cells, simian cells constitutively expressing simian virus 40 T antigen","volume":"72","author":"Hara","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.05.017_b0180","doi-asserted-by":"crossref","first-page":"632893","DOI":"10.1155\/2013\/632893","article-title":"Multiantibody strategies for HIV","volume":"2013","author":"Hiatt","year":"2013","journal-title":"Clin. Dev. Immunol."},{"issue":"1","key":"10.1016\/j.antiviral.2014.05.017_b0185","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0263-7855(96)00018-5","article-title":"VMD: visual molecular dynamics","volume":"14","author":"Humphrey","year":"1996","journal-title":"J. Mol. Graph."},{"key":"10.1016\/j.antiviral.2014.05.017_b0190","doi-asserted-by":"crossref","first-page":"4351","DOI":"10.1073\/pnas.1217537110","article-title":"Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9","volume":"110","author":"Julien","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.antiviral.2014.05.017_b0195","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/jmv.10450","article-title":"Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40","volume":"71","author":"Knowles","year":"2003","journal-title":"J. Med. Virol."},{"issue":"Suppl. 2","key":"10.1016\/j.antiviral.2014.05.017_b0200","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1080\/13550280290167894","article-title":"Overview of the cellular immunity against JC virus in progressive multifocal leukoencephalopathy","volume":"8","author":"Koralnik","year":"2002","journal-title":"J. Neurovirol."},{"key":"10.1016\/j.antiviral.2014.05.017_b0205","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jneuroim.2013.05.009","article-title":"Cerebrospinal fluid and serum JC virus antibody detection in multiple sclerosis patients treated with natalizumab","volume":"261","author":"Lin","year":"2013","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.antiviral.2014.05.017_b0210","doi-asserted-by":"crossref","first-page":"429","DOI":"10.4103\/1947-2714.100998","article-title":"Western blot: technique, theory, and trouble shooting","volume":"4","author":"Mahmood","year":"2012","journal-title":"North Am. J. Med. Sci."},{"key":"10.1016\/j.antiviral.2014.05.017_b0215","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1146\/annurev.med.080708.082655","article-title":"Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies","volume":"61","author":"Major","year":"2010","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.antiviral.2014.05.017_b0220","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1128\/JVI.61.5.1435-1441.1987","article-title":"Owl monkey astrocytoma cells in culture spontaneously produce infectious JC virus which demonstrates altered biological properties","volume":"61","author":"Major","year":"1987","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.05.017_b0225","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.molimm.2005.08.003","article-title":"Cloning and molecular characterization of a human recombinant IgG Fab binding to the Tat protein of human immunodeficiency virus type 1 (HIV-1) derived from the repertoire of a seronegative patient","volume":"43","author":"Mancini","year":"2006","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.antiviral.2014.05.017_b0230","doi-asserted-by":"crossref","first-page":"e8254","DOI":"10.1371\/journal.pone.0008254","article-title":"Hepatitis C virus (HCV) infection may elicit neutralizing antibodies targeting epitopes conserved in all viral genotypes","volume":"4","author":"Mancini","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2014.05.017_b0235","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1056\/NEJMc1207116","article-title":"Natalizumab-associated progressive multifocal leukoencephalopathy","volume":"367","author":"Mancini","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2014.05.017_b0240","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.3390\/v4091731","article-title":"Neutralization interfering antibodies: a \u201cnovel\u201d example of humoral immune dysfunction facilitating viral escape?","volume":"4","author":"Mancini","year":"2012","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2014.05.017_b0245","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1128\/JVI.56.2.365-372.1985","article-title":"Production and characterization of monoclonal antibodies to polyomavirus major capsid protein VP1","volume":"56","author":"Marriott","year":"1985","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.05.017_b0250","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.virol.2008.06.032","article-title":"SV40 vectors carrying minimal sequence of viral origin with exchangeable capsids","volume":"379","author":"Nakanishi","year":"2008","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2014.05.017_b0255","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.virol.2012.03.014","article-title":"The VP1 subunit of JC polyomavirus recapitulates early events in viral trafficking and is a novel tool to study polyomavirus entry","volume":"428","author":"Nelson","year":"2012","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2014.05.017_b0260","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.chom.2010.09.004","article-title":"Structure-function analysis of the human JC polyomavirus establishes the LSTc pentasaccharide as a functional receptor motif","volume":"8","author":"Neu","year":"2010","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.antiviral.2014.05.017_b0265","doi-asserted-by":"crossref","first-page":"e1003014","DOI":"10.1371\/journal.ppat.1003014","article-title":"Changes in JC virus-specific T cell responses during natalizumab treatment and in natalizumab-associated progressive multifocal leukoencephalopathy","volume":"8","author":"Perkins","year":"2012","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2014.05.017_b0270","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1128\/JVI.01986-07","article-title":"Identification of a broadly cross-reacting and neutralizing human monoclonal antibody directed against the hepatitis C virus E2 protein","volume":"82","author":"Perotti","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.05.017_b0275","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1099\/vir.0.008391-0","article-title":"Identification of species-specific and cross-reactive epitopes in human polyomavirus capsids using monoclonal antibodies","volume":"90","author":"Randhawa","year":"2009","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2014.05.017_b0280","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1084\/jem.179.1.323","article-title":"CDR3 length in antigen-specific immune receptors","volume":"179","author":"Rock","year":"1994","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.antiviral.2014.05.017_b0285","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.3390\/v4112924","article-title":"Molecular signatures of hepatitis C virus (HCV)-induced type II mixed cryoglobulinemia (MCII)","volume":"4","author":"Sautto","year":"2012","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2014.05.017_b0290","first-page":"289","article-title":"A phage display vector optimized for the generation of human antibody combinatorial libraries and the molecular cloning of monoclonal antibody fragments","volume":"35","author":"Solforosi","year":"2012","journal-title":"New Microbiol."},{"key":"10.1016\/j.antiviral.2014.05.017_b0295","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1007\/s11910-012-0313-4","article-title":"Update on progressive multifocal leukoencephalopathy","volume":"12","author":"Steiner","year":"2012","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/j.antiviral.2014.05.017_b0300","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00239-001-0009-x","article-title":"Evolution of human polyomavirus JC: implications for the population history of humans","volume":"54","author":"Sugimoto","year":"2002","journal-title":"J. Mol. Evol."},{"key":"10.1016\/j.antiviral.2014.05.017_b0305","doi-asserted-by":"crossref","first-page":"e1000368","DOI":"10.1371\/journal.pgen.1000368","article-title":"Adaptive mutations in the JC virus protein capsid are associated with progressive multifocal leukoencephalopathy (PML)","volume":"5","author":"Sunyaev","year":"2009","journal-title":"PLoS Genet."},{"key":"10.1016\/j.antiviral.2014.05.017_b0310","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S1474-4422(10)70124-1","article-title":"Discrepant findings in immune responses to JC virus in patients receiving natalizumab","volume":"9","author":"Tan","year":"2010","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.antiviral.2014.05.017_b0315","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/rmv.710","article-title":"Progressive multifocal leukoencephalopathy: clinical and molecular aspects","volume":"22","author":"Tavazzi","year":"2012","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.antiviral.2014.05.017_b0320","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1212\/WNL.0b013e31821a446b","article-title":"Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"76","author":"Vermersch","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.antiviral.2014.05.017_b0325","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0166-0934(98)00180-3","article-title":"Human anti-JC virus serum reacts with native but not denatured JC virus major capsid protein VP1","volume":"78","author":"Wang","year":"1999","journal-title":"J. Virol. Methods"},{"key":"10.1016\/j.antiviral.2014.05.017_b0330","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1002\/ana.1004","article-title":"Cellular and humoral immune response in progressive multifocal leukoencephalopathy","volume":"49","author":"Weber","year":"2001","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.antiviral.2014.05.017_b0335","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1177\/1756285608101861","article-title":"Natalizumab in the treatment of multiple sclerosis","volume":"2","author":"Yaldizli","year":"2009","journal-title":"Ther. Adv. Neurol. Dis."},{"key":"10.1016\/j.antiviral.2014.05.017_b0340","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1084\/jem.173.2.395","article-title":"Preferential utilization of specific immunoglobulin heavy chain diversity and joining segments in adult human peripheral blood B lymphocytes","volume":"173","author":"Yamada","year":"1991","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.antiviral.2014.05.017_b0345","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/356063a0","article-title":"Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin","volume":"356","author":"Yednock","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2014.05.017_b0350","doi-asserted-by":"crossref","first-page":"7129","DOI":"10.1021\/ac201501z","article-title":"Epitope mapping of a 95kDa antigen in complex with antibody by solution-phase amide backbone hydrogen\/deuterium exchange monitored by Fourier transform ion cyclotron resonance mass spectrometry","volume":"83","author":"Zhang","year":"2011","journal-title":"Anal. Chem."},{"key":"10.1016\/j.antiviral.2014.05.017_b0355","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.bbrc.2005.06.012","article-title":"Characterization of the VP1 loop mutations widespread among JC polyomavirus isolates associated with progressive multifocal leukoencephalopathy","volume":"333","author":"Zheng","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354214001570?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354214001570?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T12:29:36Z","timestamp":1597926576000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354214001570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":71,"alternative-id":["S0166354214001570"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2014.05.017","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cloning of the first human anti-JCPyV\/VP1 neutralizing monoclonal antibody: Epitope definition and implications in risk stratification of patients under natalizumab therapy","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2014.05.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}